Mymetics Corporation Share Price

MYMX

US62856A3005

Biotechnology & Medical Research

Market Closed - OTC Markets 17:02:13 11/05/2026 BST			5-day change	1st Jan Change
0.000300 ^USD	-.--%		-.--%	-

20/11/23	Mymetics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
18/08/23	Mymetics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI

Valuation: Mymetics Corporation

Market Cap	439K 386K 365K 331K 622K 42.12M 625K 4.37M 1.69M 21.49M 1.65M 1.61M 69.06M	P/E 2021	-1.86x	P/E 2022	-1.77x
Enterprise Value	72.12M 63.43M 59.98M 54.41M 102M 6.92B 103M 718M 277M 3.53B 271M 265M 11.35B	EV / Sales 2021	177x	EV / Sales 2022	78x
Free-Float	99.88%	Yield 2021 *	-	Yield 2022	-

* Estimated data More valuation ratios

Latest news: Mymetics Corporation

20/11/23	Mymetics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
18/08/23	Mymetics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
15/05/23	Mymetics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
11/04/23	Mymetics Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	CI
10/04/23	Mymetics Corporation Auditor Raises 'Going Concern' Doubt	CI
17/01/23	Mymetics Corporation Appoints Marcel B. Rüegg to the Board	CI
28/12/22	Mymetics Corporation Announces Resignation of Ernest M. Stern as A Member of the Board of Directors	CI
14/11/22	Mymetics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
11/08/22	Mymetics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	CI
13/05/22	Mymetics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	CI
31/03/22	Mymetics Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	CI
30/03/22	Mymetics Corporation Auditor Raises 'Going Concern' Doubt	CI
12/11/21	Mymetics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	CI

More news

Press Releases: Mymetics Corporation

11/04/23	MYMETICS CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ
27/02/23	MYMETICS CORP : Other Events (form 8-K)	AQ
08/02/23	MYMETICS CORP : Other Events (form 8-K)	AQ
17/01/23	MYMETICS CORP : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
28/12/22	MYMETICS CORP : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ

More press releases

Managers and Directors: Mymetics Corporation

Manager	Title	Age	Since
Ronald Hugo Gerard Kempers CEO	Chief Executive Officer	58	18/11/2012

More insiders

Mymetics Corporation is a vaccine company. The Company is focused on developing vaccines for infectious diseases. The Company has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.

Employees

Sector

Biotechnology & Medical Research

More about the company

Stock Market
Stocks
MYMX Stock

The best tools reserved for subscribers to boost the performance of your investments!

Current year	0		0
1 year	0		0
3 years	0		5.6
5 years	0		230
10 years	0		380

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MYMETICS CORPORATION	-.--%	-.--%	-.--%	-99.99%	45
WUXI APPTEC CO., LTD.	-0.37%	-3.67%	+57.21%	+87.75%	72.26B
ARGENX SE	-0.07%	-2.70%	+37.74%	+86.90%	60.24B
WUXI BIOLOGICS (CAYMAN) INC.	+0.75%	+0.75%	+36.71%	+21.09%	27.73B
INSMED INCORPORATED	-0.14%	-2.75%	-14.13%	+356.79%	25.73B
BIONTECH SE	+0.57%	+1.10%	+1.02%	-2.89%	24.75B
GENMAB A/S	+1.10%	+1.86%	+25.07%	-7.59%	20.74B
PHARMAESSENTIA CORPORATION	-1.70%	+0.43%	+150.24%	+323.16%	15.06B
EXELIXIS, INC.	+0.36%	+2.01%	+49.51%	+160.70%	14.41B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-2.53%	-8.15%	-6.38%	+483.59%	14.23B
Average	-0.20%	-0.10%	+33.70%	+140.95%	27.52B
Weighted average by Cap.	-0.12%	-1.08%	+38.13%	+127.84%

	2021	2022
Net sales	430K 378K 358K 324K 609K 41.28M 613K 4.28M 1.65M 21.06M 1.61M 1.58M 67.68M	1.03M 904K 855K 775K 1.46M 98.68M 1.46M 10.24M 3.95M 50.35M 3.86M 3.78M 162M
Net income	-4.73M -4.16M -3.93M -3.57M -6.7M -454M -6.74M -47.1M -18.19M -232M -17.76M -17.37M -745M	-4.8M -4.23M -4M -3.62M -6.81M -461M -6.85M -47.85M -18.48M -235M -18.04M -17.65M -756M
Net Debt	67.1M 59.01M 55.81M 50.62M 95.06M 6.44B 95.61M 668M 258M 3.29B 252M 246M 10.56B	71.68M 63.05M 59.62M 54.07M 102M 6.88B 102M 714M 276M 3.51B 269M 263M 11.28B

Mymetics Corporation Share Price

Stocks

MYMX

US62856A3005

Biotechnology & Medical Research

Valuation: Mymetics Corporation

Chart: Mymetics Corporation

Latest news: Mymetics Corporation

Press Releases: Mymetics Corporation

Price Extremes

Managers and Directors: Mymetics Corporation

Bio Therapeutic Drugs

Financials

Company Profile